Background: Atrial fibrillation (AF) is the most commonly observed arrhythmia in clinical practice and associated with increased cardiovascular morbidity and mortality. Compared to healthy population, nonvalvular AF has a 2-7 fold increased risk of ischemic stroke. The mechanisms of thrombus formation in AF are still investigated. Fibrinogen plays an active role during the coagulation process. Increased plasma fibrinogen levels were shown to be associated with the coronary heart disease, peripheral artery disease and venous thrombosis. Beta-fibrinogen 455 G/A polymorphism is a gene mutation that may lead to alterations in the activity of fibrinogen. We wanted to investigate Beta-fibrinogen 455 G/A polymorphism in patients with AF who have had a stroke than in healthy controls. Methods: The Beta-fibrinogen 455 G/A polymorphism was analysed in 70 patients with AF who have had a stroke 65 healthy individuals matched for age, race and sex. Because ethnic differences have been reported for Beta-fibrinogen 455 G/A polymorphism. The Beta-fibrinogen 455 G/A gene polymorphism was identified by polymerase chain reaction (PCR) method. Distribution of the Beta-fibrinogen 455 G/A gene polymorphism alles (allel G, allel A) genotypes (Normal (GG) genotype, heterozygous (GA) or homozygous (AA) mutant genotype) were identified in study population. Demographic characteristics and risk factors for AF and stroke were evaluated in the study groups.
Results: There was no significant difference with respect to age and gender between groups. Genotype and allel distribution of nonvalvular AF patients with ischemic stroke and control groups shown in the table. The frequency of GG genotype of Betafibrinogen 455 G/A polymorphism was significantly lower in patients with AF who have had a stroke group compared with control group (p<0,05). The frequency of GA heterozygous genotype was similar between groups. The frequency of AA homozygous mutant genotype of Beta-fibrinogen 455 G/A polymorphism was significantly higher in patients with AF who have had a stroke group compared with control group (p<0,05). Between the two groups were compared according to the dominant genetic model (GA+AA vs. GG), The number of patients carrying at least one A mutant allele (GA+AA) were significantly higher in patients with AF who have had a stroke group than controls (p<0,05). With respect to allelic distribution (G vs A, additive model), the frequency of the A mutant allele was significantly higher in CAE patients (p<0,05).
Conclusions:
In this study, we found that the frequency of b-fibrinogen 455 G/A gene polymorphism was higher in patients with AF who have had a stroke group compared to control subject. However, further large-sized studies are required for determining relationship between b-fibrinogen 455 G/A gene polymorphisms and patients with AF who have had a stroke group. 
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